ARDM Aradigm

Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2017 on February 13

HAYWARD, Calif.--(BUSINESS WIRE)--

Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda, Ph.D., will present at the 19th Annual BIO CEO & Investor Conference 2017 on Monday, February 13, 2017, at 1:30 p.m. ET. The event will be held at the Waldorf-Astoria Hotel in New York, New York.

Interested parties can access a live audio webcast and slide presentation at www.aradigm.com. An archived presentation will be available on the Company's Web site for 30 days.

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Aradigm is completing Phase 3 development of Pulmaquin® (an investigational proprietary formulation of ciprofloxacin for inhalation) for the treatment of non-cystic fibrosis bronchiectasis. Aradigm’s inhaled ciprofloxacin formulations including Pulmaquin are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax. In addition, Aradigm has a pipeline composed of programs to prevent diseases in tobacco smokers through smoking cessation and a diagnostic program to detect aspirations of gastrointestinal fluid into the respiratory tract.

More information about Aradigm can be found at www.aradigm.com.

Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation.

EN
09/02/2017

Underlying

ARDMAradigm

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aradigm

 PRESS RELEASE
Free
ARDM ARADIGM

Aradigm Announces the EMA Has Completed Its Validation of the MAA Subm...

HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced the completed formal validation by the European Medicines Agency (EMA) of the Marketing Authorisation Application (MAA) for Linhaliq for the treatment of non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic lung infections with Pseudomonas aeruginosa (P. aeruginosa). The completion of the MAA validation is commensurate with the start date of the review procedure on March 29, 2018. The EMA review of the MAA ...

April 5, 2018 1 EN
 PRESS RELEASE
Free
ARDM ARADIGM

Aradigm Announces Fourth Quarter 2017 and Full Year Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ: ARDM) (the “Company”) today announced financial results for the fourth quarter and full year ended December 31, 2017. Fourth Quarter 2017 Results The Company recorded $2.4 million in revenue in the fourth quarter of 2017 compared with $125,000 in revenue in the fourth quarter of 2016. The Company recognized $2.3 million in contract revenue – related party, $27,000 in government contract revenue and $71,000 in government grant revenue for the fourt...

March 23, 2018 1 EN
 PRESS RELEASE
Free
ARDM ARADIGM

ARADIGM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who ...

NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aradigm Corporation (“Aradigm” or the “Company”) (NASDAQ:ARDM) of the March 12, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Aradigm stock or options between July 27, 2017 and January 8, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/ARDM. There is no cost or obligation to you. ...

March 9, 2018 1 EN
 PRESS RELEASE
Free
ARDM ARADIGM

Aradigm Submits Marketing Authorisation Application (MAA) to EMA for E...

HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced it has submitted its Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Linhaliq™ for the treatment of non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic lung infection with Pseudomonas aeruginosa (P. aeruginosa). In accordance with Article 8(3) and Annex I, Part II.7 of Directive 2001/83/EC, Aradigm is submitting a mixed MAA for Linhaliq that is based on the positive Phase 3 pivota...

March 9, 2018 1 EN
 PRESS RELEASE
Free
ARDM ARADIGM

FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders of Approaching...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Aradigm Corporation (Nasdaq: ARDM) (“Aradigm” or the “Company”) securities during the period between July 27, 2017 and January 8, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until March 12, 2018 to s...

March 3, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch